Adenomas hipofisarios y adenomas funcionantes

  1. Rogelio García Centeno 1
  2. G. Collado González 1
  3. José Atencia Goñi 1
  4. Olga González Albarrán 1
  1. 1 Servicio de Endocrinología y Nutrición, Hospital General Universitario Gregorio Marañón, Madrid, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2024

Issue Title: Enfermedades endocrinológicas y metabólicas (IV)Enfermedades hipotalámicas e hipofisarias (I)

Series: 14

Issue: 16

Pages: 933-946

Type: Article

DOI: 10.1016/J.MED.2024.08.011 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Functioning pituitary adenomas (FPAs) are the most common pituitary lesions. They represent approximately 15% of all intracranial neoplasms, with prolactinomas accounting for 60% of FPAs. Its clinical manifestations are related to hypersecretion and/or local symptoms due to the tumor's mass effect, such as headache, visual disturbances, and/or hypopituitarism. The main clinical syndromes associated with pituitary hyperfunction include hyperprolactinemia with secondary hypogonadism, acromegaly, Cushing's syndrome, and secondary hyperthyroidism. Diagnosing FPA involves demonstrating an excess in hormone secretion through biochemical tests followed by imaging tests to localize the tumor. Magnetic resonance imaging (MRI) with contrast is the test of choice for this purpose. In regard to treatment, surgery is the first-line option for most FPAs except for prolactinomas, which usually respond well to dopamine agonists.

Bibliographic References

  • 1. Daly, A.F., et al. The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am. (2020)
  • 2. Ioachimescu, A.G. Sociodemographic factors in pituitary adenomas. Endocrinol Metab Clin North Am. (2023)
  • 3. Fleseriu, M., et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. (2021)
  • 4. Maiter, D. Mild hyperprolactinemia in a couple: What impact on fertility? Ann Endocrinol (Paris). (2022)
  • 5. Briet, C., et al. Thyrotropin-secreting tumor “TSH-PitNET”: From diagnosis to treatment. Ann Endocrinol (Paris). (2023)
  • 6. Ezzat, S., et al. The prevalence of pituitary adenomas: a systematic review. Cancer. (2004)
  • 7. Molitch, M.E. Diagnosis and treatment of pituitary adenomas: A review. JAMA. (2017)
  • 8. Armeni, E., et al. The spectrum of familial pituitary neuroendocrine tumors. Endocr Pathol. (2023)
  • 9. Tritos, N.A., et al. Diagnosis and management of pituitary adenomas: A review. JAMA. (2023)
  • 10. Fleseriu, M., et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. (2021)
  • 11. Díaz, C., et al. Hipersecreción de hormona de crecimiento: acromegalia gigantismo. Manual Sociedad Española de Endocrinología y Nutrición. (2019)
  • 12. Marazuela, M., et al. Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study. Endocrine. (2022)
  • 13. Puig-Domingo, M., et al. Pasireotide in the personalized treatment of acromegaly. Front Endocrinol (Lausanne). (2021)
Data source: Dialnet